Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock
Fundamentals
Recent news

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
CTNM

Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum, J&J's depression drug fails to meet mid-stage trial goal
CTNM

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
CTNM

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
CTNM
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 8 articles
published over the past 14 days
Latest news

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
CTNM

Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum, J&J's depression drug fails to meet mid-stage trial goal
CTNM

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
CTNM

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
CTNM

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
CTNM

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
CTNM

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
CTNM

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
CTNM
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Carmine N. Stengone MBA, MS | President, CEO & Director | 1976 |
| Mr. Peter T. Slover CPA | Chief Financial Officer | 1975 |
| Dr. Timothy R. Watkins M.D., M.Sc. | Chief Medical Officer & Head of Development | 1974 |
| Ms. Morgan Paulsen | Senior Manager of Accounting | — |
| Dr. Daniel S. Lorrain Ph.D. | Chief Science Officer | 1969 |
| Mr. Steve E. Kunszabo | Senior Director of Investor Relations & Corporate Communications | — |
| Mr. John S. Healy | General Counsel & Corporate Secretary | 1972 |
| Mr. Austin Chen Ph.D. | Senior VP & Head of Research | — |
| Ms. Julie S. Iwashita | Senior Vice President of Clinical Operations | — |
| Ms. Kristina Haeckl Rac | Senior Vice President of Regulatory Affairs | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +1.6 | +1.9 | -24.1 |



